Literature DB >> 27497913

Parkinson's disease: Autoimmunity and neuroinflammation.

Armando De Virgilio1, Antonio Greco2, Giovanni Fabbrini3, Maurizio Inghilleri3, Maria Ida Rizzo4, Andrea Gallo5, Michela Conte2, Chiara Rosato5, Mario Ciniglio Appiani1, Marco de Vincentiis2.   

Abstract

Parkinson's disease is a neurodegenerative disease that causes the death of dopaminergic neurons in the substantia nigra. The resulting dopamine deficiency in the basal ganglia leads to a movement disorder that is characterized by classical parkinsonian motor symptoms. Parkinson's disease is recognized as the most common neurodegenerative disorder after Alzheimer's disease. PD ethiopathogenesis remains to be elucidated and has been connected to genetic, environmental and immunologic conditions. The past decade has provided evidence for a significant role of the immune system in PD pathogenesis, either through inflammation or an autoimmune response. Several autoantibodies directed at antigens associated with PD pathogenesis have been identified in PD patients. This immune activation may be the cause of, rather than a response to, the observed neuronal loss. Parkinsonian motor symptoms include bradykinesia, muscular rigidity and resting tremor. The non-motor features include olfactory dysfunction, cognitive impairment, psychiatric symptoms and autonomic dysfunction. Microscopically, the specific degeneration of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies, which are brain deposits containing a substantial amount of α-synuclein, have been recognized. The progression of Parkinson's disease is characterized by a worsening of motor features; however, as the disease progresses, there is an emergence of complications related to long-term symptomatic treatment. The available therapies for Parkinson's disease only treat the symptoms of the disease. A major goal of Parkinson's disease research is the development of disease-modifying drugs that slow or stop the neurodegenerative process. Drugs that enhance the intracerebral dopamine concentrations or stimulate dopamine receptors remain the mainstay treatment for motor symptoms. Immunomodulatory therapeutic strategies aiming to attenuate PD neurodegeneration have become an attractive option and warrant further investigation.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmunity; Inflammation; Lewy bodies; Neurodegenerative disease; Olfactory dysfunction; Parkinson; α-Synuclein

Mesh:

Year:  2016        PMID: 27497913     DOI: 10.1016/j.autrev.2016.07.022

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  84 in total

1.  DNA Methyltransferase 1 Is Dysregulated in Parkinson's Disease via Mediation of miR-17.

Authors:  Hong-Qiu Zhang; Jian-Yong Wang; Zhao-Feng Li; Lei Cui; Shi-Shi Huang; Lan-Bing Zhu; Yue Sun; Rui Yang; Hui-Hui Fan; Xiong Zhang; Jian-Hong Zhu
Journal:  Mol Neurobiol       Date:  2021-01-22       Impact factor: 5.590

2.  Parkinson disease-associated LRRK2 G2019S transgene disrupts marrow myelopoiesis and peripheral Th17 response.

Authors:  Jeongho Park; Jang-Won Lee; Scott C Cooper; Hal E Broxmeyer; Jason R Cannon; Chang H Kim
Journal:  J Leukoc Biol       Date:  2017-07-27       Impact factor: 4.962

3.  Microglial autophagy defect causes parkinson disease-like symptoms by accelerating inflammasome activation in mice.

Authors:  Jinbo Cheng; Yajin Liao; Yuan Dong; Han Hu; Nannan Yang; Xiangxi Kong; Shuoshuo Li; Xiaoheng Li; Jifeng Guo; Lixia Qin; Jiezhong Yu; Cungen Ma; Jianke Li; Mingtao Li; Beisha Tang; Zengqiang Yuan
Journal:  Autophagy       Date:  2020-01-31       Impact factor: 16.016

4.  Expression profiling suggests microglial impairment in human immunodeficiency virus neuropathogenesis.

Authors:  Stephen D Ginsberg; Melissa J Alldred; Satya M Gunnam; Consuelo Schiroli; Sang Han Lee; Susan Morgello; Tracy Fischer
Journal:  Ann Neurol       Date:  2018-02-10       Impact factor: 10.422

5.  Intragastric Administration of Casein Leads to Nigrostriatal Disease Progressed Accompanied with Persistent Nigrostriatal-Intestinal Inflammation Activited and Intestinal Microbiota-Metabolic Disorders Induced in MPTP Mouse Model of Parkinson's Disease.

Authors:  Xinrong Liu; Shuya Liu; Yong Tang; Zhengjia Pu; Hong Xiao; Jieying Gao; Qi Yin; Yan Jia; Qunhua Bai
Journal:  Neurochem Res       Date:  2021-03-15       Impact factor: 3.996

Review 6.  Shedding light on thyroid hormone disorders and Parkinson disease pathology: mechanisms and risk factors.

Authors:  S Mohammadi; M Dolatshahi; F Rahmani
Journal:  J Endocrinol Invest       Date:  2020-06-04       Impact factor: 4.256

Review 7.  Autoimmunity in 2016.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 8.  Utilization of the CRISPR-Cas9 Gene Editing System to Dissect Neuroinflammatory and Neuropharmacological Mechanisms in Parkinson's Disease.

Authors:  Jie Luo; Piyush Padhi; Huajun Jin; Vellareddy Anantharam; Gary Zenitsky; Qian Wang; Auriel A Willette; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  J Neuroimmune Pharmacol       Date:  2019-03-16       Impact factor: 4.147

9.  Cross-Reactivity and Sequence Homology Between Alpha-Synuclein and Food Products: A Step Further for Parkinson's Disease Synucleinopathy.

Authors:  Aristo Vojdani; Aaron Lerner; Elroy Vojdani
Journal:  Cells       Date:  2021-05-05       Impact factor: 6.600

10.  Nurr1 promotes neurogenesis of dopaminergic neuron and represses inflammatory factors in the transwell coculture system of neural stem cells and microglia.

Authors:  Xiao-Xiang Chen; Yuan Qian; Xiang-Peng Wang; Zhi-Wei Tang; Jiao-Tian Xu; Hai Lin; Zhi-Yong Yang; Xiao-Bin Song; Di Lu; Jia-Zhi Guo; Li-Gong Bian; Yu Li; Lei Zhou; Xing-Li Deng
Journal:  CNS Neurosci Ther       Date:  2018-02-15       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.